The two trials from which the data was pull were LUX-Lung 3 and LUX-Lung 6.
The analysis of the data from the trials suggests that a reduction in specific doses was the contributing factor to the decrease in incidences and severity of adverse events related to treatments in patients who have been treated for afatinib without any obvious compromise in efficiency.
"Afatinib's efficacy and safety profile in the first-line treatment of patients with EGFR mutation-positive NSCLC has been well established in multiple large trials," James Chih-Hsin Yang, principal investigator and lead author, said. "This further analysis suggests that dosing of afatinib can be adjusted to help manage a patient's treatment-related adverse events, without any apparent reduction in efficacy. This may provide physicians and their patients with confidence and allows physicians to help address adverse events."
Yang is also the director of the Department of Oncology at National Taiwan University Hospital and director of the Graduate Institute of Oncology at National Taiwan University Cancer Center in Taiwan.